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Abstract
Background: The majority of dogs with diabetes mellitus develop 
blinding mature cataracts through the action of the enzyme aldose 
reductase producing sorbitol with osmotic action drawing water into 
the lens thus causing opacification. Here we evaluate the use of 
OcuGLO™ a formulation including the aldose reductase inhibitor 
alpha lipoic acid, grapeseed extract, carotenoids, omega-3-fatty 
acids, and coenzyme Q10 in the prevention of canine diabetic 
cataract in a prospective placebo-controlled double-masked study.
Materials and methods: Dogs with diabetes mellitus but as yet 
without the development of blinding diabetic cataracts were given 
either OcuGLO™ or a placebo containing antioxidant vitamins. 
Dogs were examined monthly and their degree of lens opacification 
documented photographically using a Genesis D fundus camera at 
+10D. Time to progression of lens opacification was documented 
and compared between the OcuGLO™ group and the placebo 
group, using Kaplan Meier survival curve statistics.
Results: Mean time without change in lens opacification was 278 ± 
184 days with OcuGLO Rx™ and 77 ± 40 days in the placebo group 
this difference being statistically significant at p=0.0005. Twelve of 
15 dogs taking the placebo developed significantly increased lens 
opacification while 5 of 15 dogs taking OcuGLO Rx™ developed 
significant cataract. of these five dogs four animals did not receive 
daily OcuGLO Rx™ as directed due to unrelated concurrent illness 
or owner non-compliance. The remaining dog progressed despite 
Ocu-GLO Rx™ administration. In two dogs, diabetic cataract was 
reversed with regained vision on Ocu-GLO Rx™.
Discussion: This small preliminary study demonstrates that oral 
Ocu-GLO Rx™ has beneficial effects in delaying cataract formation 
in dogs with diabetes mellitus. We look forward to further studies 
with larger case populations but note that the statistical significance 
reached between placebo and supplement-treated group, even 
with a small study population, demonstrates the efficacy of this 
commercially available dietary supplement.
Introduction
Cataract formation is a widely recognised complication of 
diabetes mellitus in the dog [1]. Lens opacification in diabetes is 
suggested to occur through three mechanisms. The first and most 
important in the dog is the accumulation of polyols, sugar alcohols 
and most particularly sorbitol, produced through the action of the 
enzyme aldose reductase (AR) and resulting in an osmotic stress 
and ingress of fluid into the lens, causing cataract [2]. While this 
development of lens opacity is generally considered to be rapid, 
changing a clear lens to a mature cataract within hours or days, and 
occurring bilaterally symmetrically in both eyes, these assumptions 
may not necessarily be correct, formed through the fact that most 
ophthalmologists will only see diabetic dogs when they have become 
blind. In fact, initial changes in lens opacity prior to the development 
of mature cataract may occur in diabetic dogs with equatorial 
vacuoles and cortical opacities occurring in a substantial number of 
cases, and not necessarily occurring bilaterally symmetrically. Similar 
changes are seen in dogs fed galactose [3], but the cataract formation 
may be more severe in this experimental model, since the osmoticon 
produced by AR from galactose, galacticol, is not further metabolised 
to fructose by an enzyme equivalent to sorbitol dehydrogenase. 
Inhibition of aldose reductase has been shown to prevent galactose 
and diabetic cataract in a number of experimental models [4-6], and 
in some cases reversal of diabetic cataract on use of sorbinil, an aldose 
reductase inhibitor, has been reported [7].
The other two mechanisms involve non-enzymatic glycation 
of lens proteins [8] and oxidative stress [9], which may itself occur 
through the competition between AR and glutathione reductase for 
NADPH leading to a depletion in reduced glutathione (GSH), a key 
intralenticular antioxidant. The part played by these mechanisms in 
the canine lens is at present unknown.
It has already been demonstrated that administration of the 
topical AR inhibitor Kinostat appears to inhibit the development of 
cataracts in diabetic dogs, but this product is not as yet commercially 
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available and does not have these prophylactic effects in every treated 
dog [10]. Here we seek to show that a commercially available product, 
Ocu-GLO Rx™, which includes the AR inhibitor alpha lipoic acid, 
together with a set of antioxidant and free radical scavenging moieties 
already shown to have beneficial effects in reducing cataractogenesis, 
is effective in preventing formation of diabetic cataracts in dogs and 
even in reversing diabetic cataract in a small number of animals. 
Anecdotal evidence was already available suggesting that Ocu-
GLO Rx™ did prevent cataractogenesis in diabetic dogs but clearly 
a double-masked placebo-controlled study was required to confirm 
these findings in a controlled manner.
Alpha lipoic acid is a potent antioxidant, a potent metal chelator 
and scavenger of hydroxyl radicals, hypoclorous acid and singlet 
oxygen species. It also functions to regenerate oxidized glutathione, 
coenzyme Q10 and vitamins C and E to their reduced forms [11-16]. 
The compound’s reduced form, dihydrolipoic acid, acts as a scavenger 
of superoxide and a potent inhibitor of lipid peroxidation. Alpha 
lipoic acid has been shown to have beneficial effects in several models 
of diabetes, namely the streptozocin-induced diabetic cataract in rats 
[17]. It has also been shown to act as an AR inhibitor [18] although 
with a lower activity than previously investigated AR inhibitors such 
as sorbinil.
Grapeseed extract contains proanthrocyanins, oligomers 
and polymers of polyhydroxyfalavan-3-ols such as catechin and 
epicatechin, present as polyphenols in red wine and in grape 
seeds. These compounds have strong antioxidative and free radical 
scavenging activity and have anti-cataractogenic effects in diabetic rats 
[19], in rats with hereditary cataracts [20], and in rats with selenite-
induced cataracts [21]. Coenzyme Q10, also known as ubiquinone, is 
a benzoquinone component of the mitochondrial respiratory chain, 
in addition to its antioxidant effects. It acts as a free radical scavenger 
and is widely recognised as a protectant against oxidative stress in 
a number of systems. Green tea extract contains epigallocatechin 
gallate (EGCG) a catechin with acts as a powerful antioxidant and has 
been shown in a mouse model to modify progression to the diabetic 
state [22,23] as well as to alleviate oxidative damage in the rat eye 
[24] and inhibit cataract formation in the rat streptozotocin-induced 
diabetes model [25,26].
Given the importance of oxidative stress in cataractogenesis, and 
the central role played by AR in the formation of diabetic cataracts, 
the combination of antioxidant moieties and AR inhibitor activity 
in Ocu-GLO Rx™ can be understood as acting to promote its anti-
cataractogenic activity. But is there firm evidence for such effects? 
Studies to determine the cataract-impeding effects of a number of 
molecules have produced less than definitive results in the human 
field, principally because it is difficult to confine a human subject 
to a specific dietary regime. Epidemiological studies have sought to 
correlate degree of cataract with dietary inputs in humans with limited 
success. Interventional studies are notoriously difficult to implement 
and to interpret, but interestingly in relation to Ocu-GLO Rx™ being a 
mix of different compounds, one of the most successful interventional 
studies on dietary amelioration of age related cataractogenesis is the 
REACT (Roche European American Cataract Trial) protocol [27], 
which demonstrated a significant ameliorative effect on generation of 
age-related lens opacities in people. While investigations such as the 
VetCat study [28] failed to show an effect of vitamin E on impeding 
development of age-related cataract in people, it was dietary regimes 
requiring a mix of antioxidant products which yielded beneficial 
results.
In a veterinary field study, the topical AR inhibitor, Kinostat [5], 
has demonstrated anti-cataractogenic results. In a multicentre trial 
with 28 dogs receiving Kinostat and 12 receiving placebo, seven dogs 
(14 eyes) in the placebo group developed mature cataracts, 2 dogs 
(4 eyes) developed cortical opacities, and 1 dog (2 eyes) developed 
equatorial vacuoles, compared with 4 dogs (8 eyes) in the Kinostat 
group developing mature cataracts, 2 dogs (4 eyes) developing 
cortical opacities, and 1 dog (2 eyes) developing equatorial vacuoles. 
Here we demonstrate what might be considered even better results 
with a once daily oral formulation, which has demonstrated even 
more impressive results than with three times daily topical Kinostat.
Materials and Methods
This prospective placebo-controlled double-masked study 
compared time to onset and/or progression of cataract in diabetic 
dogs treated once daily with Ocu-GLO Rx™ per os with onset and/or 
progression of cataracts in diabetic dogs given an oral placebo capsule 
once daily containing vitamin antioxidants but without alpha lipoic 
acid, grapeseed extract, carotenoids, or coenzyme Q10.
Dogs involved in the study were client-owned companion 
animals accessed from five first opinion veterinary clinics visited by 
DLW in an ambulatory ophthalmology referral service providing 
consultations at those clinics regularly. Clients gave full informed 
consent and agreed to give the relevant supplement daily per os and 
attend consultations monthly at which photographs of lenses would 
be taken after pharmacological mydriasis, as well as to inform DLW 
immediately of any change in their dog’s behaviour suggestive of 
deterioration in visual acuity.
All dogs were being treated with daily or twice daily injections 
of insulin and were stable and in good health in other respects, their 
endocrine disease being monitored by their referring veterinarians. 
Evaluation of the recent medical history in each dog showed that the 
diabetes was under control, and also that no concurrent disease was 
present at the time of admission to the study, which might complicate 
the study. Animals in which laboratory results or clinical findings 
indicated concurrent disease at the time of commencement of the 
trial were excluded from the study.
The dogs were given Ocu- GLO Rx™ or the placebo per os in a 
capsule with the capsule size related to the weight of the dog to 
normalise the dose of antioxidants with regard to the weight of the 
animal.
The study was reviewed and accepted by the welfare and ethics 
committee of the Department of Veterinary Medicine, University of 
Cambridge. Given previous anecdotal evidence that Ocu-GLO Rx™ 
would prevent cataract formation in diabetic dogs and the published 
successful results of the topical AR inhibitor in Kinostat to do the 
same [5], the use of a placebo group where lens opacification would 
be allowed to progress to a mature cataract then requiring surgery 
was considered unethical, especially as the animals involved would 
be client-owned dogs. It was thus decided that the end point for the 
study in each dog would be significant progression of lens opacity, 
as documented photographically rather than progression to mature 
cataract. If lens opacification had progressed in any dog in the study, 
the trial would be stopped for that animal and its treatment group 
would be unmasked. Were the dog to be on the placebo, it would then 
be transferred to the supplement arm of the study. In each animal on 
either arm of the study, time to progression of cataract, where such 
progression occurred, was used as the endpoint for use in the Kaplan-
Meier survival plot statistics and time without cataract progression 
used where lens transparency did not change.
A power calculation showed that 12 dogs in each arm of the 
study would yield a valid result with 80% power given that in one 
year 75% of the animals would be expected to develop cataract and 
it was anticipated that Ocu-GLO Rx™ Rx™ would reduce this to 25%. 
To ensure a statistically valid result, 15 dogs in each arm of the study 
were chosen as the population size required.
Statistical analysis comparing the times to cataract progression 
in the two arms of the study was undertaken with the Kaplan-Meier 
estimator using SPSS software.
Blood samples were taken by the referring veterinarians during 
the study for blood glucose and fructosamine analysis but samples 
could not be taken for evaluation of serum alpha lipoic acid levels 
or levels of other antioxidant moieties, as the study was undertaken 
under the Veterinary Surgeons Act (1966) and not the Animal 
Scientific Procedures Act (1988). Therefore, in the UK blood samples 
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could only be taken for the immediate benefit of the animals involved 
and not to answer a scientific research question.
Results
Signalment of dogs entered into the study is detailed in tables 1 for 
dogs on the supplement and placebo arms of the study respectively. 
All dogs were diagnosed on the basis of the clinical signs of polydipsia 
and polyuria, weight loss in the face of polyphagia and laboratory 
findings of hyperglycaemia with glucosuria. All dogs were being 
treated with subcutaneous insulin injections. Duration of time since 
diagnosis of diabetes and fructosamine levels at the beginning of the 
study is given in tables 1. The average length of time the animals had 
been on the study was 240 ± 142 days with a range  of between 618 
and 48 days.
Six dogs had no signs of lens opacification at the commencement 
of the study while others had some lens changes such as nuclear 
sclerosis (16 dogs), equatorial vacuoles (7 dogs) or cortical spokes 
(19 dogs), some of which (nuclear sclerosis and cortical spokes, for 
instance) were consistent with age-related changes while others 
(particularly equatorial vacuoles) were consistent with the lens 
pathology seen in canine diabetic hyperglycaemia. Details of lens 
pathology are given in table 2 together with time on the study without 
change in lens opacification.
Mean time without change in lens opacification at the time of 
writing was 278±184 days with Ocu-GLO Rx™ and 77 ± 40 days in 
the placebo group. Median duration without lens change was 261 and 
84 days, respectively, this difference being statistically significant at 
p=0.0003.
Twelve of the 15 dogs (80%) taking the placebo developed 
significant lens changes while on the study protocol. Five of 15 
dogs (33%) taking Ocu-GLO Rx™ developed significant cataract, 
in three of these animals Ocu-GLO Rx™ was not being given 
as directed due to pancreatitis leading to vomiting and thus 
presumed insufficient supplement intake, and in one dog inability 
Table 1: Signalment of dogs on supplement and placebo arms of study
case Supplement/placebo breed gender Age (years) Fructosamine (µmol/L) Duration of diabetes (months)
1 supplement dachshund fn 11 385 18
2 supplement dachshund fn 11 405 18
3 supplement rough collie fn 9 423 4
4 supplement border collie fn 11 546 8
6 supplement cross-bred me 9.6 453 2
7 supplement golden retriever me 8.7 546 8
8 supplement labrador retriever mn 9 778 13
9 supplement labrador cross mn 11 457 7
14 supplement beagle mn 7.8 513 12
16 supplement cross-bred mn 12.8 657 5
17 supplement lowchen mn 15.2 544 6
18 supplement minature poodle fn 13 354 3
21 supplement cross-bred mn 3 555 3
22 supplement siberian husky fn 12 533 3
13 supplement dobermann fn 9 367 9
2 placebo dachshund fn 11 405 18
5 placebo labrador cross mn 9 778 13
7 placebo golden retriever me 8.7 546 8
9 placebo labrador cross mn 11 457 7
10 placebo cross-bred me 12 342 4
11 placebo cross-bred fn 9.9 602 5
12 placebo minature poodle fn 13 354 3
13 placebo dobermann fn 9 367 9
15 placebo west highland white terrier mn 8 546 4
19 placebo collie cross fn 9 435 3
20 placebo west highland white terrier fn 10.3 422 8
14 placebo beagle me 12 546 2
23 placebo jack russell terrier me 10.9 523 4
24 placebo border collie mn 9 342 3
25 placebo cross-bred fn 10.9 401 3
mn: male neutered, me:  male entire, fn: female neutered, fe: female entire
Table 2: Lens pathology at start of trial and time to significant deterioration in lens 










1 supplement mc cs 618
2 supplement cs cs 590
3 supplement fco fco 84 *
4 supplement fco fco 540
6 supplement fco fco 256
7 supplement fco fco 234
8 supplement nco nco 209 *
9 supplement nco nco 270
13 supplement ev ev 92 *
14 supplement fco fco 180
16 supplement ev ev 191
17 supplement cl cl 261
18 supplement cl cl 68 *
21 supplement fco fco 128 *
22 supplement cl cl 361
2 placebo mc fco 28 *
5 placebo fco fco 84 *
7 placebo nco fco 80 *
9 placebo ppsco ppsco 112 *
10 placebo fco fco 56 *
11 placebo fco fco 58 *
12 placebo cl cl 26 *
13 placebo ev fco 41 *
*15 placebo fco fco 48 *
19 placebo fco fco 174
20 placebo ev ev 148
14 placebo cl cl 132
23 placebo ppsco ppsco 88 *
24 placebo co co 59 *
25 placebo no nco 57 *
cl: clear lens, cs: cortical spokes, ev: equatorial vacuoles, fco: focal cortical 
opacities, mc: mature cataract, no: nuclear opacity, nco: nuclear and cortical 
opacities, ppsco: posterior subcapsular opacity
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of the elderly arthritic owner to ensure that the dog swallowed 
the capsule daily, again led to insufficient supplement intake. 
One animal, apparently taking the capsule daily and in normal 
health apart from its diabetic state, developed cataract in the 
face of treatment. Two dogs, Dachshund siblings, one of which 
presented with lenticular opacity at the beginning of the study and 
the other of which developed the opacity while on the placebo, 
both regained vision in their cataractous eye while on Ocu-GLO 
RxTM as documented photographically in Figure 1. A Kaplan-
Meier survival plot of the data for each arm of the study is shown 
in Figure 2.
Discussion
Cataract is a well-recognised complication of diabetes mellitus 
in the dog, with 70% of cases developing sight-threatening lens 
opacification within 12 months of diagnosis [29]. As noted in the 
introduction, lens changes in the face of hyperglycaemia are thought 
to be caused by the action of the enzyme AR, which converts glucose 
in the lens to sorbitol. Sorbitol is normally produced in the lens to 
counteract the dehydrating activity of high extracellular glucose 
during normal physiological hyperglycaemia after eating [30] but 
in situations of persistent hyperglycaemia, as seen in diabetes for 
instance, the generation of excess intracellular sorbitol leads to 
osmotic stress and swelling of lens fibre cells. Recent work in lenses of 
diabetic rats has questioned whether AR activity is the key player in 
diabetic cataractogenesis in that species [31]. It is likely that oxidative 
stress also plays a part in cataract development in diabetes, as it does 
in the ageing changes seen in the non-diabetic lens.
Here we show that the formulation Ocu-GLO Rx™ has a 
significant beneficial effect in reducing the development of sight-
threatening mature cataract in diabetic dogs. It might be argued 
that this preliminary study involves a small number of dogs, yet 
the fact that a highly significant difference is seen with only fifteen 
dogs in each arm of the study demonstrates that the medication has 
a highly significant effect. We aim to further this study examining 
the beneficial effect of Ocu-GLO Rx™ on a larger number of dogs as 
clinical cases in a multicentre study to address the small number of 
animals in the current study.
The formulation Ocu-GLO Rx™ has been developed to include 
both the AR inhibitor and glutathione regenerator alpha lipoic acid, as 
well as a number of anti-oxidant moieties such as EGCG (containing 
quercetin), grapeseed extract, various carotenoids (lutein, zeaxanthin 
and lycopene), and coenzyme Q10 with the aim of reducing oxidative 
stress in the diabetic lens. It might be argued that such a mix of 
molecules with differing actions aimed at preventing cataractogenesis 
in these diabetic dogs does not provide sufficient rigour in allowing 
dissection of the different molecular actions important in impeding 
lens opacification. We acknowledge this potential deficit in the 
current study, which is aimed at assessing the value of Ocu-GLO Rx™ 
as a clinical tool in preventing cataract formation in diabetic dogs 
rather than specifically as a scientific assessment of the molecular 
mechanisms of cataractogenesis in diabetic dogs. We may further this 
study by evaluating the effects of individual agents in this product, but 
note that the paucity of success in preventing cataract formation in 
human studies using individual agents has been overshadowed by the 
favourable outcomes in human trials employing a mixture of agents, 
such as the Roche European American Cataract Trial (REACT). We 
suggest that, in a similar fashion here, a mix of agents may be more 
efficacious than the sum of its parts.
The decision not to have progression to full blinding lens 
opacification as the end point might similarly be questioned. Using 
total blindness with a mature cataract as the endpoint might been seen 
as a more definitive endpoint, but as discussed above, it was decided 
that an endpoint of significant change in lens opacification should be 
used with dogs on placebo being transferred to the active treatment 
arm of the trial. This has the advantage of showing that Ocu-GLO 
Rx™ appears to prevent further cataract formation in diabetic dogs 
where early changes such as equatorial vacuoles or cortical spokes 
have occurred.
Using client-owned animals might be seen as problematic in that 
owners may have supplemented their animals with other products or 
with Ocu-GLO Rx™, but since in the UK the product was not available 
at the time of the study and all owners agreed not to supplement their 
         
Figure 1: Lens changes in two diabetic dachshund siblings on OcuGLO (left) 
and placebo (right)
         
Figure 2: Kaplan Meier survival plot showing proportion of eyes with clear 
lenses over time in days for population of dogs given supplement (black line) 
and those on placebo (dotted line).
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dogs other than with the trial formulations this is unlikely to have 
confounded the study. The fact that a range of dog breeds was involved 
might also complicate the study if some breeds are more likely to 
develop denser lens opacities as is seen between human patients of 
different ethnicities, but we have no evidence currently that diabetic 
cataract in different dog breeds varies in a similar manner.
In conclusion this study provides preliminary data demonstrating 
that Ocu-GLO Rx™ impedes cataractogenesis in diabetic dogs. Further 
studies to enlarge the case population will be necessary and are in the 
planning stages, but to have obtained a highly significant difference 
between dogs on the supplement and those on placebo even at this 
small sample size may be taken as a preliminary demonstration of 
the efficacy of this dietary supplement in diabetic cataract in the dog. 
The importance of aldose reductase and oxidative changes in the 
pathogenesis of other diabetic complications in human patients [32] 
suggests that use of an aldose reductase inhibitor and antioxidant 
cocktail such as this product may be valuable in human patients quite 
as much as in dogs.
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